Compare Eni SpA (E) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eni SpA vs IDEXX Laboratories, Inc. — how do they compare? Eni SpA trades at $48.36 (market cap $70.34B), while IDEXX Laboratories, Inc. trades at $574.5 (market cap $43.94B). The key difference: Eni SpA is the larger of the two by market cap, and Eni SpA pays a 4.99% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| E | IDXX | |
|---|---|---|
Market Cap | $70.34B | $43.94B |
Sector | Energy | Health |
52-Week High | $57.61 | $766.68 |
52-Week Low | $32.93 | $514.61 |
Enterprise Value | $89.25B | $44.84B |
Dividend Yield | 4.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eni (E) trades at $49.55, up 0.22% with a bullish technical signal supported by moving averages. The company shows stable cash flow generation with $238M net cash flow in 2025 and maintains a dividend of $0.63. Recent strategic expansions into renewable fuels, lithium, and energy trading through partnerships with BMW, Mercuria, and UKAEA highlight diversification efforts. Valuation metrics appear reasonable with P/E of 21.6 and EV/EBITDA of 3.83, though revenue has declined from $132.5B in 2022 to $82.15B in 2025.
The outlook balances strategic growth initiatives against revenue pressures. Opportunities exist in energy transition projects and trading expansion, but risks include oil price volatility and execution challenges. Analyst sentiment is mixed with 34.6% buy ratings versus 61.5% hold, suggesting cautious optimism. The stock's investment case hinges on successful diversification while managing core energy market exposure.
IDXX stock trades at $540.68, down 4.15% in the last session, with technical indicators showing a bearish bias. Fundamentally, the company demonstrates strong profitability with a 24.63% net margin and consistent earnings beats in recent quarters. Revenue growth continues, reaching $4.3B in 2025. Analyst sentiment remains predominantly positive with a 59% buy rating, though technical signals conflict with this fundamental strength.
The outlook balances robust fundamentals against technical weakness. Investment opportunity lies in sustained high profitability and market leadership in veterinary diagnostics, but risks include elevated valuation multiples (P/E 40.99) and bearish technical momentum that may pressure the stock near-term despite positive analyst coverage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eni SpA
Eni is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, the company produced 0.8 million barrels of liquids and 4.6 billion cubic feet of natural gas per day. At end-2021, Eni held reserves of 6.6 billion barrels of oil equivalent, 49% of which are liquids. The Italian government owns a 30.1% stake in the company. Eni is placing its renewable and low-carbon business in a separate entity, Plentitude
Read more on E →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
